Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas

Prolactin-secreting adenomas are the most frequent type among pituitary tumors, and pharmacological therapy with dopamine agonists remains the mainstay of treatment. But some adenomas are resistant, and a decrease in the number or function of dopamine D2 receptors (D2Rs) has been described in these...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luque, G.M., Perez-Millán, M.I., Ornstein, A.M., Cristina, C., Becu-Villalobos, D.
Formato:	JOUR
Materias:	aflibercept dopamine dopamine 2 receptor monoclonal antibody monoclonal antibody G6-31 prolactin unclassified drug vasculotropin vasculotropin receptor 2 animal experiment animal model animal tissue antiangiogenic activity article cancer inhibition cancer transplantation controlled study female mouse nonhuman priority journal prolactinoma protein blood level protein expression signal transduction tumor vascularization Angiogenesis Inhibitors Animals Antibodies, Monoclonal Cell Proliferation Dopamine Female Hyperplasia Mice Mice, Inbred C57BL Mice, Knockout Microvessels Neovascularization, Pathologic Pituitary Gland Pituitary Neoplasms Prolactin Prolactinoma Receptors, Dopamine D2 Recombinant Fusion Proteins Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor Receptor-1
Acceso en línea:	http://hdl.handle.net/20.500.12110/paper_00223565_v337_n3_p766_Luque
Aporte de:	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

Ejemplares similares

Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas
Publicado: (2011)

Dopaminergic D2 receptor knockout mouse: An animal model of prolactinoma
por: Cristina, C., et al.

Dopaminergic D2 receptor knockout mouse: An animal model of prolactinoma
Publicado: (2006)

Local VEGF inhibition prevents ovarian alterations associated with ovarian hyperstimulation syndrome
por: Abramovich, Dalhia Nurit, et al.
Publicado: (2014)

Local VEGF inhibition prevents ovarian alterations associated with ovarian hyperstimulation syndrome
por: Scotti, L., et al.

Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary
por: Recouvreux, M.V., et al.

Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary
Publicado: (2011)

The dopamine D 2 , but not D 3 or D 4 , receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice
por: Ralph, R.J., et al.

Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: Detection of a non-endothelial function of VEGF in pituitary tumours
por: Onofri, C., et al.
Publicado: (2006)

Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: Detection of a non-endothelial function of VEGF in pituitary tumours
por: Onofri, C., et al.

Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: Detection of a non-endothelial function of VEGF in pituitary tumours
por: Onofri, C., et al.
Publicado: (2006)

The dopamine D 2 , but not D 3 or D 4 , receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice
Publicado: (1999)

Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: Detection of a non-endothelial function of VEGF in pituitary tumours
Publicado: (2006)

New insights into the endocrine and metabolic roles of dopamine D2 receptors gained from the Drd2-/- mouse
por: Garcia-Tornadú, I., et al.

New insights into the endocrine and metabolic roles of dopamine D2 receptors gained from the Drd2-/- mouse
Publicado: (2010)

Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice
por: Cristina, C., et al.

PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes
por: Cristina, C., et al.

PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes
Publicado: (2007)

Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice
Publicado: (2005)

Detection of endothelial cells by MEC 13.3 monoclonal antibody in mice mammary tumors
por: Vanzulli, S., et al.

Sex differences in the pituitary transforming growth factor-β1 system: Studies in a model of resistant prolactinomas
por: Recouvreux, M.V., et al.

Detection of endothelial cells by MEC 13.3 monoclonal antibody in mice mammary tumors
por: Gazzaniga, Silvina N., et al.
Publicado: (1997)

Sex differences in the pituitary transforming growth factor-β1 system: Studies in a model of resistant prolactinomas
Publicado: (2013)

Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors
por: Croci, D.O., et al.

Angiotensina II en la hipófisis normal e hiperplásica
por: González Iglesias, Arturo E.
Publicado: (2001)

Angiotensina II en la hipófisis normal e hiperplásica
por: González Iglesias, Arturo E.
Publicado: (2001)

Angiotensina II en la hipófisis normal e hiperplásica
por: González Iglesias, Arturo E.
Publicado: (2001)

Neurotransmitter modulation of the GHRH-GH axis
por: García-Tornadu, I., et al.

Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors
Publicado: (2014)

Neurotransmitter modulation of the GHRH-GH axis
Publicado: (2010)

Central dopamine D2 receptors regulate growth-hormone- dependent body growth and pheromone signaling to conspecific males
por: Noaín, D., et al.

Caracterización del sistema TGF-ß1 hipofisario : en búsqueda de un blanco terapéutico para prolactinomas resistentes a agonistas dopaminérgicos
por: Recouvreux, María Victoria
Publicado: (2012)

Caracterización del sistema TGF-ß1 hipofisario : en búsqueda de un blanco terapéutico para prolactinomas resistentes a agonistas dopaminérgicos
por: Recouvreux, María Victoria
Publicado: (2012)

Caracterización del sistema TGF-ß1 hipofisario : en búsqueda de un blanco terapéutico para prolactinomas resistentes a agonistas dopaminérgicos
por: Recouvreux, María Victoria
Publicado: (2012)

Central dopamine D2 receptors regulate growth-hormone- dependent body growth and pheromone signaling to conspecific males
Publicado: (2013)

Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice
por: Cristina, C., et al.

GH in the dwarf dopaminergic D2 receptor knockout mouse: Somatotrope population, GH release, and responsiveness to GH-releasing factors and somatostatin
por: García-Tornadú, I., et al.

GH in the dwarf dopaminergic D2 receptor knockout mouse: Somatotrope population, GH release, and responsiveness to GH-releasing factors and somatostatin
Publicado: (2006)

Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice
Publicado: (2007)

Spatiotemporal analysis of the protein expression of angiogenic factors and their related receptors during folliculogenesis in rats with and without hormonal treatment
por: Abramovich, Dalhia Nurit, et al.
Publicado: (2009)